Remus Pharma posts FY26 H2 and full-year results with revenue up 37.6% to ₹853.63 Cr, PAT ₹46.17 Cr, and ongoing portfolio expansion into GLP‑1, CNS, and anti-infective segments.
AI Assistant
Remus Pharmaceuticals Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.